$173.53 0.00 (%) Amgen Inc - NASDAQ

Sep. 26, 2016 | 04:00 PM

Partner Headlines

  1. Biotech ETFs Lead Q3 Rally: XBI Breaks Out

    TalkMarkets | Sep. 22, 2016 | 21:00PM EST
  2. 2 Biotech Funds Leading Nascent Bull Market: Which Is Right For You?

    Investors Business Daily | Aug. 2, 2016 | 16:09PM EST
  3. QQQ ETF Posts 52-Week High; Energy Stocks Sag As Oil Drops To $40

    Investors Business Daily | Aug. 1, 2016 | 18:08PM EST
  4. What's Driving The Biotech Stock Rally? And Will It Last?

    Investors Business Daily | Aug. 1, 2016 | 15:15PM EST
  5. Are Biotechs Finally Making A Comeback? Here Are 5 Must-Watch Names

    Investors Business Daily | Aug. 1, 2016 | 12:20PM EST
  6. Apple, Facebook, Alphabet, Amazon, Ford, McDonald's Headline Busy Week

    Investors Business Daily | Jul. 29, 2016 | 12:13PM EST
  7. Amgen Beats Q2 Earnings Estimates, Raises Guidance

    Investors Business Daily | Jul. 27, 2016 | 16:28PM EST
  8. Facebook, GoPro, Amgen Beat; Whole Foods Disappoints

    Investors Business Daily | Jul. 27, 2016 | 16:20PM EST
  9. Nasdaq Up As Fed Stands Pat On Rates; Will Apple Break Its Downtrend?

    Investors Business Daily | Jul. 27, 2016 | 14:17PM EST
  10. Alder Biopharma Migraine Drug Holds Up After 6 Months

    Investors Business Daily | Jul. 25, 2016 | 11:05AM EST
  11. This Week Could Decide Whether Biotech ETFs' Rally Sizzles Or Fizzles

    Investors Business Daily | Jul. 25, 2016 | 05:00AM EST
  12. Week In Review: Stock Breakouts, Netflix Subs Snub, Tesla's Plan, M&A News

    Investors Business Daily | Jul. 22, 2016 | 12:25PM EST
  13. Lilly, J&J, Novo Battle For Diabetes Market Heats Up; FDA Rulings Loom

    Investors Business Daily | Jul. 22, 2016 | 10:44AM EST
  14. Chardan Upgrades Regeneron Amid Relative Underperformance To Amgen Shares

    Benzinga | Feb. 16, 2016 | 08:33AM EST
  15. Gilead, Johnson & Johnson or Roche?

    GuruFocus | Feb. 11, 2016 | 12:15PM EST
  16. Amgen, Celgene Buck Short Interest Trend In Biotech Stocks

    Benzinga | Feb. 11, 2016 | 07:49AM EST
  17. Chardan: Sell Regeneron After Sanofi Drops Patent Infringement Bombshell

    Benzinga | Feb. 10, 2016 | 09:30AM EST
  18. The Generic Drug Battle

    Benzinga | Feb. 10, 2016 | 09:13AM EST
  19. Regeneron Q4 Earnings Miss Estimates Amid Slow Praluent Launch

    IBD | Feb. 9, 2016 | 11:28AM EST
  20. Schoenebaum: Biotech P/Es Show 'Buying Signal' With Caveat; Amgen, Biogen, Celgene & Gilead Have Catalysts

    Benzinga | Feb. 8, 2016 | 15:27PM EST
  21. Pharmaceuticals Turn To Politics To Protect Prices

    Benzinga | Feb. 8, 2016 | 08:17AM EST
  22. Leerink Is Back On Board The Biotech Train

    Benzinga | Feb. 5, 2016 | 10:32AM EST
  23. LinkedIn Downgraded; Biotechs Initiated; Tableau PT Cut

    IBD | Feb. 5, 2016 | 09:16AM EST
  24. Plenty of Opportunity to Buy Individual Stocks: John Buckingham

    GuruFocus | Feb. 2, 2016 | 12:32PM EST
  25. Maybe Some Good News For A Big Biotech ETF

    Benzinga | Jan. 29, 2016 | 08:39AM EST
  26. Why Amazon, Microsoft, Xerox And Amgen Are Moving After-Hours

    Benzinga | Jan. 28, 2016 | 16:52PM EST
  27. Earnings Recap For January 28

    Benzinga | Jan. 28, 2016 | 16:34PM EST
  28. FDA Accepts Amgen's Biosimilar Biologics License Application For ABP 501

    Benzinga | Jan. 25, 2016 | 17:21PM EST
  29. Regeneron Is Now A Sell For Chardan

    Benzinga | Jan. 25, 2016 | 08:40AM EST
  30. Big Earnings Expectations For Big Biotech

    Benzinga | Jan. 24, 2016 | 16:55PM EST
  31. Amgen's Vectibix, Best Supportive Care Improves Overall Survival vs BSC In Chemorefractory KRAS, RAS Wild-Type mCRC

    Benzinga | Jan. 23, 2016 | 15:57PM EST
  32. Amgen's Repatha) Approved in Japan as First PCSK9 Inhibitor for Treatment of High Cholesterol

    Benzinga | Jan. 22, 2016 | 04:21AM EST
  33. Medicines Company Spikes On Report Of Possible Sale

    IBD | Jan. 20, 2016 | 12:59PM EST
  34. Jim Cramer Likes Amgen

    Benzinga | Jan. 20, 2016 | 06:40AM EST
  35. Write A Prescription For This Healthcare ETF

    Benzinga | Jan. 15, 2016 | 08:24AM EST
  36. Stocks Reverse Higher To Big Gains; Intel Falls After Q4 Results

    IBD | Jan. 14, 2016 | 16:29PM EST
  37. Stocks, Mutual Funds Rose In Q4 Despite Dec. Woes

    IBD | Jan. 8, 2016 | 18:22PM EST
  38. Jim Cramer Gives His Opinion On Lockheed Martin And Gilead Sciences

    Benzinga | Jan. 7, 2016 | 06:35AM EST
  39. 3 Potential Blockbuster Drugs Launching in 2016

    IBD | Jan. 6, 2016 | 09:42AM EST
  40. Mid-Afternoon Market Update: Netflix Drops Following Baird Downgrade; Lululemon Shares Rise

    Benzinga | Jan. 4, 2016 | 15:01PM EST
  41. Mid-Day Market Update: Baxalta Shares Surge Amid Report Of Shire Interest; Canadian Solar Shares Slide

    Benzinga | Jan. 4, 2016 | 12:15PM EST
  42. Mid-Morning Market Update: Markets Open Lower; Tesla Motors Delivers 17,400 Vehicles in Fourth Quarter

    Benzinga | Jan. 4, 2016 | 10:10AM EST
  43. Benzinga's Top #PreMarket Gainers

    Benzinga | Jan. 4, 2016 | 08:13AM EST
  44. Alan Fournier Sells GM, Buys Molson Coors Brewing

    GuruFocus | Jan. 3, 2016 | 13:24PM EST
  45. The 5 Top-Performing Big-Cap Drug Stocks Of 2015

    IBD | Dec. 30, 2015 | 14:16PM EST
  46. Dividend Growth Skids To Halt For S&P 500

    IBD | Dec. 30, 2015 | 08:02AM EST
  47. 5 Guru Picks in Volatile Biotech Industry

    GuruFocus | Dec. 23, 2015 | 14:24PM EST
  48. Benzinga's M&A Chatter for Monday December 21, 2015

    Benzinga | Dec. 21, 2015 | 19:59PM EST
  49. Big Cap 20 Stocks Setting Up In Bases

    IBD | Dec. 21, 2015 | 18:31PM EST
  50. Analyzing Amgen's Dividend Hike

    GuruFocus | Dec. 21, 2015 | 00:03AM EST
Trading Center